Article Text

PDF

215 Active arthritis is associated with 14–3–beta titre in patients with systemic lupus erythematosus
  1. C Hitchon,
  2. D Robinson,
  3. H El-Gabalawy,
  4. A Tisseverasinghe,
  5. A Man and
  6. C Peschken
  1. University of Manitoba, Internal Medicine, Winnipeg, Canada

Abstract

Background and aims Non-erosive arthritis is common in systemic lupus erythematosus (SLE). 14-3-3 eta, a chaperone protein that activates pro-inflammatory pathways is emerging as a novel biomarker for erosive Rheumatoid Arthritis. We investigated clinical associations of serum 14-3-3 eta in SLE focusing on arthritis.

Methods Sociodemographics, ACR criteria, and SLEDAI were recorded. Arthritis, assessed by the SLEDAI, was categorised as active (n=78), inactive (n=138) and never present (n=49). Serum 14-3-3 eta was measured by ELISA; titres above 0.19 ng/ml were considered positive. We report descriptive statistics and logistic regression models testing the association of 14-3-3eta with arthritis state.

Results SLE patients (n=265) were mainly female (92%), Caucasian (67%) with a mean (SD) age of 51.7 (14) years, and median (25%,75%) disease duration of 8 (4,10) years, number ACR criteria of 6 (5,7), and SLEDAI of 4 (2,7). 241 (81%) had active or inactive arthritis. 14-3-3 eta positivity was similar across the three arthritis groups (active 22/78 (28%), inactive 27/138 (20%), never present 10/49 (20%) with a median (25%75%) titre of 0.6 ng/ml (0.34, 1.82). The highest quartile of 14-3-3eta associated with active arthritis (OR 3.6 (95% CI 1.33, 9.98) p-0.012) after adjusting for ethnicity and SLEDAI. There were no differences in 14-3-3 eta positivity for other lupus criteria nor correlation of 14-3-3 eta titer with number of ACR criteria or SLEDAI.

Conclusions 14-3-3 eta titers are highest in lupus patients with active arthritis suggesting a higher risk for more severe arthritis. Further work will explore the associations of 14-3-3 eta in lupus with erosive arthritis.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.